Results 111 to 120 of about 322,762 (264)
mir‐196a promotes Esophagus Adenocarcinoma aggressiveness. On one hand, mir‐196a targets the valosin‐containing protein (VCP) mRNA, causing the accumulation of c‐MYC protein that leads to high amounts of TERT. On the other hand, mir‐196a targets the inhibitor of NFκB (NFKBIA).
Jesús García‐Castillo +8 more
wiley +1 more source
Retracted: Mo-Si-B Alloy Formed by Optional Laser Melting Process
International Journal of Analytical Chemistry
doaj +1 more source
Research and education in analytical chemistry - industrial and academic perspectives from a survey conducted in Sweden. [PDF]
Bergquist J +3 more
europepmc +1 more source
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine +10 more
wiley +1 more source
International Journal of Analytical Chemistry
doaj +1 more source
Green analytical chemistry and experimental design: a combined approach for the analysis of zonisamide. [PDF]
Elsheikh SG +3 more
europepmc +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Retracted: Electrochemical Preparation of Nanocatalysts and Their Application in Electrocatalysis
International Journal of Analytical Chemistry
doaj +1 more source
Greener and Whiter Analytical Chemistry Using Cyrene as a More Sustainable and Eco-Friendlier Mobile Phase Constituent in Chromatography. [PDF]
El Deeb S, Abdelsamad K, Parr MK.
europepmc +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source

